A class of investors that claim Pfizer’s Wyeth Pharmaceuticals unit concealed the extent of health risks from its touted antidepressant Pristiq has been certified in Manhattan federal court.
In a 12-page order on Sept. 18, Southern District Judge Richard Sullivan rejected arguments by Pfizer’s lawyers at Simpson Thacher & Bartlett that the pension fund acting as lead plaintiff in the case is an inadequate class representative because of its relationship with plaintiffs lawyers Robbins Geller Rudman & Dowd.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
